Pathology of IgA Nephropathy

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2014 May 28

PMID 24861083

Citations 113

Authors

Ian S D Roberts

Affiliations

Soon will be listed here.

Abstract

IgA nephropathy is defined by the presence of IgA-dominant or co-dominant immune deposits within glomeruli. Biopsy specimens meeting these diagnostic criteria have a range of histological changes that are reflected in the variable clinical course of IgA nephropathy. The impact of histology on outcomes in IgA nephropathy has been clarified in a number of large retrospective clinicopathological studies. These studies have consistently demonstrated that the stage of disease at presentation, as indicated by the extent of interstitial fibrosis and tubular atrophy in the biopsy, is the strongest histological predictor of renal survival. The effect of active proliferative lesions on the disease course is less clear cut, owing in part to considerable treatment bias in most published retrospective studies. There is evidence that endocapillary hypercellularity and cellular crescents are responsive to immunosuppressive therapy, but this observation requires confirmation in prospective randomized controlled trials. Future challenges include improving the reproducibility of histological scoring, particularly for the presence and extent of endocapillary lesions, and to improve prognostic modelling by combining histological data with clinical variables and biomarker data.

Citing Articles

Single-Cell Analysis of Endothelial Cell Injury in IgA Nephropathy.

Yang Y, Zhu L, Zhao J, Zhang B, Wang X, Cheung W Immun Inflamm Dis. 2025; 13(2):e70149.

PMID: 39945225 PMC: 11822453. DOI: 10.1002/iid3.70149.

Targeting endoplasmic reticulum stress: an innovative therapeutic strategy for podocyte-related kidney diseases.

Lv J, Yu H, Du S, Xu P, Zhao Y, Qi W J Transl Med. 2025; 23(1):95.

PMID: 39838496 PMC: 11752968. DOI: 10.1186/s12967-025-06076-3.

Urinary TYROBP and HCK as genetic biomarkers for non-invasive diagnosis and therapeutic targeting in IgA nephropathy.

Xie B, Pang S, Xie Y, Tan Q, Li S, Jili M Front Genet. 2025; 15():1516513.

PMID: 39777260 PMC: 11703869. DOI: 10.3389/fgene.2024.1516513.

An inflammatory cytokine signature predicts IgA nephropathy severity and progression.

Chen L, Chen X, Cai G, Jiang H, Chen X, Zhang M MedComm (2020). 2024; 5(11):e783.

PMID: 39492831 PMC: 11531656. DOI: 10.1002/mco2.783.

Hepatitis C-Induced Immunoglobulin A (IgA) Nephropathy: An Uncommon Cause of Hematuria.

Kakumani J, Narne K, Koduri A, Lankapothu P, S M Cureus. 2024; 16(9):e70168.

PMID: 39463595 PMC: 11505565. DOI: 10.7759/cureus.70168.

References

Herzenberg A, Fogo A, Reich H, Troyanov S, Bavbek N, Massat A . Validation of the Oxford classification of IgA nephropathy. Kidney Int. 2011; 80(3):310-7. DOI: 10.1038/ki.2011.126. View

Manno C, Torres D, Rossini M, Pesce F, Schena F . Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009; 24(12):3694-701. DOI: 10.1093/ndt/gfp356. View

Yau T, Korbet S, Schwartz M, Cimbaluk D . The Oxford classification of IgA nephropathy: a retrospective analysis. Am J Nephrol. 2011; 34(5):435-44. DOI: 10.1159/000332223. View

Karoui K, Hill G, Karras A, Moulonguet L, Caudwell V, Loupy A . Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies. Kidney Int. 2010; 79(6):643-654. DOI: 10.1038/ki.2010.460. View

Ikezumi Y, Suzuki T, Imai N, Ueno M, Narita I, Kawachi H . Histological differences in new-onset IgA nephropathy between children and adults. Nephrol Dial Transplant. 2006; 21(12):3466-74. DOI: 10.1093/ndt/gfl455. View

Roberts I, Brenchley P . Mast cells: the forgotten cells of renal fibrosis. J Clin Pathol. 2000; 53(11):858-62. PMC: 1731105. DOI: 10.1136/jcp.53.11.858. View

Katafuchi R, Ninomiya T, Nagata M, Mitsuiki K, Hirakata H . Validation study of oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011; 6(12):2806-13. PMC: 3255377. DOI: 10.2215/CJN.02890311. View

Seedat Y, Nathoo B, Parag K, Naiker I, Ramsaroop R . IgA nephropathy in blacks and Indians of Natal. Nephron. 1988; 50(2):137-41. DOI: 10.1159/000185144. View

Jennette J . The immunohistology of IgA nephropathy. Am J Kidney Dis. 1988; 12(5):348-52. DOI: 10.1016/s0272-6386(88)80022-2. View

10.

Bellur S, Troyanov S, Cook H, Roberts I . Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant. 2011; 26(8):2533-6. DOI: 10.1093/ndt/gfq812. View

11.

Brodsky S, Rovin B, Hebert L . Benefit of cyclophosphamide therapy in IgA nephritis may have been obscured by warfarin-related nephropathy in the randomized trials in which warfarin and dipyridamole were used in combination with cyclophosphamide. Nephrol Dial Transplant. 2011; 27(2):475-7. DOI: 10.1093/ndt/gfr559. View

12.

Nieuwhof C, Kruytzer M, Frederiks P, Van Breda Vriesman P . Chronicity index and mesangial IgG deposition are risk factors for hypertension and renal failure in early IgA nephropathy. Am J Kidney Dis. 1998; 31(6):962-70. DOI: 10.1053/ajkd.1998.v31.pm9631840. View

13.

VANGELISTA A, Frasca G, Mondini S, Bonomini V . Idiopathic IgA mesangial nephropathy: immunohistological features. Contrib Nephrol. 1984; 40:167-73. DOI: 10.1159/000409745. View

14.

Furness P, Taub N . International variation in the interpretation of renal transplant biopsies: report of the CERTPAP Project. Kidney Int. 2001; 60(5):1998-2012. DOI: 10.1046/j.1523-1755.2001.00030.x. View

15.

Lee S, Rao V, Franklin W, Schiffer M, Aronson A, SPARGO B . IgA nephropathy: morphologic predictors of progressive renal disease. Hum Pathol. 1982; 13(4):314-22. DOI: 10.1016/s0046-8177(82)80221-9. View

16.

Harper L, Ferreira M, Howie A, Savage C, Richards N, Michael J . Treatment of vasculitic IgA nephropathy. J Nephrol. 2000; 13(5):360-6. View

17.

Roberts I, Cook H, Troyanov S, Alpers C, Amore A, Barratt J . The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76(5):546-56. DOI: 10.1038/ki.2009.168. View

18.

Novak J, Tomana M, Matousovic K, Brown R, Hall S, Novak L . IgA1-containing immune complexes in IgA nephropathy differentially affect proliferation of mesangial cells. Kidney Int. 2005; 67(2):504-13. DOI: 10.1111/j.1523-1755.2005.67107.x. View

19.

Oka K, Imai E, Moriyama T, Akagi Y, Ando A, Hori M . A clinicopathological study of IgA nephropathy in renal transplant recipients: beneficial effect of angiotensin-converting enzyme inhibitor. Nephrol Dial Transplant. 2000; 15(5):689-95. DOI: 10.1093/ndt/15.5.689. View

20.

Bogenschutz O, Bohle A, Batz C, Wehrmann M, Pressler H, Kendziorra H . IgA nephritis: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol. 1990; 10(2):137-47. DOI: 10.1159/000168068. View